Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $2.05 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA remained flat at $1.72 during trading on Friday. 3,274,544 shares of the company's stock traded hands, compared to its average volume of 2,673,386. The stock has a market cap of $352.60 million, a P/E ratio of 2.73 and a beta of 0.91. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The stock has a 50-day moving average price of $1.66 and a two-hundred day moving average price of $1.94. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TSHA shares. Chardan Capital restated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Finally, Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.